Tags

Type your tag names separated by a space and hit enter

[Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy].
Rofo. 2004 Sep; 176(9):1285-95.ROFO

Abstract

PURPOSE

To quantify changes of bone marrow microcirculation in multiple myeloma (MM) using contrast enhanced dynamic MRI (dMRI) during thalidomide as antiangiogenic monotherapy or in combination with chemotherapy (cyclophosphamide, etoposide, dexamethasone).

MATERIALS AND METHODS

The study includes 63 patients with refractory or relapsed MM, who underwent dMRI with high temporal resolution (T1w-turboFLASH) of the lumbar spine before and following treatment. The contrast uptake was quantified using a two compartment model with the output parameters amplitude and k (ep) (exchange rate constant). The evaluation considered the initial dMRI finding (pathological or non-pathological) and the clinical therapeutic response (response or no response).

RESULTS

During monotherapy with thalidomide (n = 38), no significant changes of the dMRI parameters were found, even when considering the initial dMRI finding (positive n = 22) and the therapeutic response (responder n = 14). The combination with chemotherapy (n = 25) had a significant reduction of k (ep) (p = 0.01) in 18 patients with positive initial dMRI finding and therapeutic response. Reduction of the amplitude was seen in most cases, but in the end without any significance (p = 0.09).

CONCLUSION

dMRI can quantify significant changes of bone marrow microcirculation solely during treatment with thalidomide combined with chemotherapy, not with thalidomide alone.

Authors+Show Affiliations

Abteilung Onkologische Diagnostik und Therapie, Deutsches Krebsforschungszentrum, Heidelberg. k.wasser@dkfz.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Controlled Clinical Trial
English Abstract
Journal Article

Language

ger

PubMed ID

15346264

Citation

Wasser, K, et al. "[Dynamic MRI of the Bone Marrow for Monitoring Multiple Myeloma During Treatment With Thalidomide as Monotherapy or in Combination With CED Chemotherapy]." RoFo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin, vol. 176, no. 9, 2004, pp. 1285-95.
Wasser K, Moehler T, Neben K, et al. [Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy]. Rofo. 2004;176(9):1285-95.
Wasser, K., Moehler, T., Neben, K., Nosas, S., Heiss, J., Goldschmidt, H., Hillengass, J., Düber, C., Kauczor, H. U., & Delorme, S. (2004). [Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy]. RoFo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin, 176(9), 1285-95.
Wasser K, et al. [Dynamic MRI of the Bone Marrow for Monitoring Multiple Myeloma During Treatment With Thalidomide as Monotherapy or in Combination With CED Chemotherapy]. Rofo. 2004;176(9):1285-95. PubMed PMID: 15346264.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy]. AU - Wasser,K, AU - Moehler,T, AU - Neben,K, AU - Nosas,S, AU - Heiss,J, AU - Goldschmidt,H, AU - Hillengass,J, AU - Düber,C, AU - Kauczor,H U, AU - Delorme,S, PY - 2004/9/4/pubmed PY - 2004/10/8/medline PY - 2004/9/4/entrez SP - 1285 EP - 95 JF - RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin JO - Rofo VL - 176 IS - 9 N2 - PURPOSE: To quantify changes of bone marrow microcirculation in multiple myeloma (MM) using contrast enhanced dynamic MRI (dMRI) during thalidomide as antiangiogenic monotherapy or in combination with chemotherapy (cyclophosphamide, etoposide, dexamethasone). MATERIALS AND METHODS: The study includes 63 patients with refractory or relapsed MM, who underwent dMRI with high temporal resolution (T1w-turboFLASH) of the lumbar spine before and following treatment. The contrast uptake was quantified using a two compartment model with the output parameters amplitude and k (ep) (exchange rate constant). The evaluation considered the initial dMRI finding (pathological or non-pathological) and the clinical therapeutic response (response or no response). RESULTS: During monotherapy with thalidomide (n = 38), no significant changes of the dMRI parameters were found, even when considering the initial dMRI finding (positive n = 22) and the therapeutic response (responder n = 14). The combination with chemotherapy (n = 25) had a significant reduction of k (ep) (p = 0.01) in 18 patients with positive initial dMRI finding and therapeutic response. Reduction of the amplitude was seen in most cases, but in the end without any significance (p = 0.09). CONCLUSION: dMRI can quantify significant changes of bone marrow microcirculation solely during treatment with thalidomide combined with chemotherapy, not with thalidomide alone. SN - 1438-9029 UR - https://www.unboundmedicine.com/medline/citation/15346264/[Dynamic_MRI_of_the_bone_marrow_for_monitoring_multiple_myeloma_during_treatment_with_thalidomide_as_monotherapy_or_in_combination_with_CED_chemotherapy]_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-2004-813414 DB - PRIME DP - Unbound Medicine ER -